6 June 2002
Hong Kong - Cheung Kong (Holdings) Ltd (Cheung Kong) would like to announce that certain shares in CK Life Sciences Int'l; (Holdings) Inc (CK Life Sciences) will be allocated to qualifying shareholders of Cheung Kong at the time of listing of CK Life Sciences. Application for the separate listing of CK Life Sciences was submitted on May 10, and approval for the listing by GEM Listing Committee is in progress.

Qualifying shareholders of Cheung Kong will be entitled to subscribe one CK Life Sciences share for every 25 shares held. This entitlement is offered to all transfers lodged with the Registrar no later than 4 pm on June 20, 2002. Should the proposed spin-off be postponed, further announcement on the latest date of transfer will be made.

In order that more CK Life Sciences shares will be offered to the qualifying shareholders of Cheung Kong, Mr Li Ka-Shing, Chairman of Cheung Kong, and the Li family trust, as shareholders of Cheung Kong, had decided not to take up the entitlement. As such, Li Ka-Shing Unity Trustee Company Limited (TUT), companies controlled by TUT and any associates of Mr Li Ka-shing would not be extended the entitlement.

CK Life Sciences is primarily engaged in the business of research and development, commercialisation, marketing, and sale of biotechnology products. The company's business areas cover two dimensions - human health and environmental sustainability. Products developed by CK Life Sciences are categorised into five areas, namely eco-agriculture, bioremediation, pharmaceuticals, nutraceuticals and dermatologicals.